Mochi Health GLP-1 Review 2026: Specialist Care and Flat-Rate Pricing — With Significant Caveats

Mochi Health, founded in 2022 by Dr. Myra Ahmad — a UCSF-trained obesity medicine physician — is built around a clinical premise that most telehealth GLP-1 platforms ignore: obesity is a complex medical condition that requires the expertise of board-certified obesity medicine specialists, not general practitioners prescribing to questionnaires.

The platform executes on that premise with genuine clinical depth. Board-certified obesity medicine physicians conduct required video consultations. Registered dietitians are included in the standard $79/month membership. The compounded medication pricing is flat-rate at all doses — $99/month for semaglutide and $199/month for tirzepatide regardless of where you are in titration — eliminating the cost increases that catch patients off guard at competing platforms. The result is 100,000+ patients, a 4.4/5 Trustpilot rating from 15,000+ reviews, and published outcome data showing an average 36 pounds lost in year one.

This review must also be honest about what is working less well. Mochi primarily uses compounded medications, and the platform faces legal and operational challenges that prospective members deserve to understand before enrolling. This review covers both sides.

The Editorial Framing for WeightRx Guide Readers

WeightRx Guide covers FDA-approved telehealth providers. Mochi Health's primary product — compounded semaglutide at $99/month — uses a medication that is not FDA-approved. The platform does also navigate insurance for brand-name Wegovy and Zepbound, making it a dual-track platform in the same way that some other reviewed platforms (Noom Med, for example) offer both compounded and brand-name paths.

This review evaluates Mochi on both its brand-name insurance track (which is our primary editorial focus) and its compounded track, with clear labeling throughout.

What Mochi Health Offers

The medication menu

The flat-rate pricing advantage

The $99/month flat rate for compounded semaglutide at all doses is Mochi's most structurally distinctive feature. Most platforms that offer compounded semaglutide either increase the price at higher doses or charge per-dose. Mochi's flat rate means:

• At dose 0.25 mg: $99/month
• At dose 2.4 mg (maintenance): $99/month
• No surprise cost increase at any titration step

For patients using compounded semaglutide long-term, this is genuinely valuable. The all-in cost ($178/month: $79 membership + $99 medication) is transparent, predictable, and among the lowest for a clinically supervised compounded program that includes a registered dietitian.

The clinical model

Mochi's clinical infrastructure is the most impressive of any platform reviewed:

Board-certified obesity medicine physicians. Mochi explicitly requires board certification in obesity medicine, internal medicine, family medicine, endocrinology, or related specialties. Most telehealth GLP-1 platforms do not specify specialty credentials — providers are often general practitioners or nurse practitioners prescribing to intake questionnaires. Mochi's specialty credential requirement means patients are seen by clinicians with specific training in metabolic health and weight management.

Required video consultations. Every patient has a video visit before their first prescription. This is higher standard than async-only platforms (Hims, GoodRx) and ensures the prescribing clinician has actually spoken with and seen the patient.

Registered dietitian included. 30-minute RD video visits are schedulable through the patient portal at no additional charge. The RD provides nutrition counseling, meal planning support, and GLP-1-specific dietary guidance — including protein strategies to mitigate lean muscle loss. As our diet article on this site covers, protein targeting is the most important dietary variable for GLP-1 patients, and most platforms leave patients entirely on their own for this. Mochi's included RD access is a genuine clinical differentiator at the $79/month membership price.

Consistent provider relationship. The same physician manages your care throughout — you do not get a different provider at each visit. If the relationship is not working, you can switch providers in the patient portal directly.

Insurance Navigation for Brand-Name GLP-1s

For patients whose commercial insurance covers Wegovy or Zepbound, Mochi has a dedicated insurance navigation team that handles prior authorizations. Patient reviews consistently cite this team as effective — multiple reviews describe insurers approving coverage that the patient's own primary care doctor said was impossible.

What the insurance track provides:

• Insurance benefit verification before enrolling on the brand-name track
• Prior authorization submission and management
• Appeal support if initial PA is denied
• Coordination of manufacturer savings cards when coverage is approved
• The Wellness Plus plan for insured patients adds advanced nutrition therapy, custom diet planning, behavioral therapy, and health screenings at $0 additional cost

For insured patients, the brand-name PA pathway at Mochi can reduce medication cost to $25/month with the appropriate savings card — making total all-in cost approximately $104/month ($79 membership + $25 medication). That is competitive with Ro's annual plan and WW Clinic's insured pricing.

A critical disclosure: Brand-name medication pricing is not publicly disclosed by Mochi. Cash-pay prices for brand-name options are not listed on the website — you must request a prescription to see costs. For patients specifically seeking brand-name cash-pay access at competitive pricing, this opacity is a genuine limitation. Ro, Hims, and GoodRx all publish brand-name cash pricing upfront.

The Regulatory and Legal Concerns

This section addresses material risks that prospective Mochi members should understand before enrolling.

The Eli Lilly Lawsuit

Eli Lilly filed a lawsuit against Mochi Health alleging that the platform changed patient tirzepatide doses en masse — in batch protocol changes applied to patients without individual consultation — at least five times in eight months. If the allegation is accurate, this represents a clinical standard-of-care failure: GLP-1 dose changes should be based on individual patient response and provider assessment, not applied systemically to patient populations without consultation.

Mochi disputes the claims. An earlier Eli Lilly lawsuit against Mochi was dismissed by a federal court — Mochi was found not liable in that case. The current lawsuit was active at time of publication. We will update this review as the case proceeds.

The lawsuit's specific allegation — mass dose changes without individual provider consultation — is worth taking seriously given Mochi's stated commitment to personalized obesity medicine care. Patients should ask Mochi directly how dose protocol changes are managed.

The Aequita Pharmacy Shutdown

In March 2025, Washington State shut down Aequita, Mochi's primary compounding pharmacy partner at the time, for sterile compounding violations. This caused widespread disruption to Mochi patients — medication supply interruptions, delayed refills, and the need to transition to new pharmacy partners.

Sterile compounding violations are serious: improperly compounded injectable medications can cause infections, contamination-related harm, or loss of potency. Mochi has since transitioned to other compounding pharmacy partners. The platform's current pharmacy partners had not been independently verified at the time of this review's publication.

Billing Complaints

Consistent with the pattern seen across the broader telehealth GLP-1 market, Mochi has significant billing complaint volume: the $79 membership is non-refundable after 24 hours, multi-month plans cannot be prorated for early cancellation, and patients report charges continuing after cancellation requests. These complaints are common across telehealth platforms — Noom Med, WW Clinic, and Calibrate have similar patterns — but they are prominent in Mochi's user review data.

If enrolling, document your enrollment date, screenshot the cancellation policy at sign-up, and cancel via the patient portal with written confirmation before the next billing cycle if you need to exit the program.

Outcome Data

Mochi is one of the few platforms in this review series to publish specific outcome claims with associated methodology:

• Average 10% body weight loss at 6 months
• Average 36 pounds lost in year one
• 5 out of 6 members stay at least a second month (retention indicator)

These figures are company-published, not peer-reviewed, and reflect the self-selecting patient population that remains engaged with the program. They are broadly consistent with clinical trial data for semaglutide and tirzepatide but cannot be directly compared without understanding the patient population characteristics.

The high Trustpilot score (4.4/5 from 15,000+ reviews) suggests a high rate of genuine patient satisfaction, particularly on clinical quality. The most consistent positive feedback: the quality of the obesity medicine provider relationship, successful insurance prior authorizations for brand-name medications, and the included RD access.

Who Mochi Is Right For

Mochi is the strongest choice if:

• You have commercial insurance and want active prior authorization support for brand-name Wegovy or Zepbound — particularly if previous PA attempts have been denied
• You value seeing a board-certified obesity medicine specialist rather than a general practitioner
• You want a registered dietitian included in your plan without paying extra
• You have made an informed decision to use compounded semaglutide and want the flat-rate pricing at all doses from a platform with the strongest clinical oversight model among compounded providers
• You need access in all 50 states

Mochi is not the right choice if:

• You want only FDA-approved brand-name medications without compounded alternatives as part of the platform — Ro, Hims, Amazon One Medical, GoodRx, or WW Clinic are better
• The active Eli Lilly lawsuit and Aequita pharmacy shutdown create unacceptable uncertainty for you
• You need transparent brand-name cash-pay pricing before committing
• You want a structured behavioral change curriculum (Noom, WW) rather than dietitian access

How Mochi Compares

Mochi vs. Ro Body Program

Ro is brand-name only with a Novo Nordisk partnership; Mochi is primarily compounded with insurance navigation for brand-name. For brand-name-focused patients, Ro's model is cleaner. For insured patients where either platform's PA team can secure coverage, the programs are competitive — Mochi's included RD is an advantage over Ro's coaching curriculum. For compounded medication patients: Mochi at $178/month all-in undercuts every brand-name platform except Ro's annual plan.

Mochi vs. Calibrate

Calibrate requires commercial insurance, excludes T2D, and is insurance-first. Mochi accepts both insured and self-pay. Calibrate's biweekly video coaching is more intensive; Mochi's obesity medicine specialist + dietitian is more clinically credentialed. For insured patients wanting maximum clinical rigor: Calibrate. For patients wanting the specialist-level care without the year-long Calibrate commitment: Mochi.

Mochi vs. WW Clinic

WW Clinic is brand-name only with a 21% outcome claim; Mochi is primarily compounded with stronger clinical credentials. WW Clinic's community, Points system, and lifestyle infrastructure are unmatched. Mochi's obesity medicine board certification is unmatched. For lifestyle program + GLP-1: WW Clinic. For specialist clinical care: Mochi.

Our Verdict

WeightRx Guide Rating: 3.6 / 5

Mochi Health's clinical model is genuinely the strongest among platforms in its price tier — board-certified obesity medicine physicians, required video visits, included RD, and flat-rate pricing at all compounded doses are a combination no comparable platform matches.

The 3.6 rating reflects the material concerns that cannot be set aside: active Eli Lilly litigation over dose management practices, the March 2025 pharmacy partner shutdown for sterile compounding violations, significant billing complaint volume, and non-transparent brand-name pricing. These are not minor operational friction points. For a platform where compounded injectable medications are the core product, pharmacy quality and prescribing protocol transparency are foundational clinical safety concerns.

Our recommendation: Mochi's strongest use case in 2026 is as an insurance navigation platform for brand-name GLP-1s. The PA team is well-regarded in patient reviews, the Wellness Plus insured plan is comprehensive, and the obesity medicine specialist relationship is a clinical asset. For that path — insured patients pursuing Wegovy or Zepbound coverage with active support — Mochi's clinical model is competitive with Ro and WW Clinic.

For compounded medication patients: the flat-rate pricing and specialist oversight are genuine advantages over simpler compounding platforms, but the Aequita shutdown and Lilly lawsuit create risks that patients should weigh carefully.

Frequently Asked Questions

Is Mochi Health primarily a compounded medication platform?

Yes. Mochi's most prominently priced options are compounded semaglutide ($99/month flat rate) and compounded tirzepatide ($199/month flat rate). Compounded medications are not FDA-approved. Mochi does also navigate insurance for brand-name Wegovy and Zepbound for insured patients, but these medications are accessed through insurance rather than as a direct cash-pay offering with published pricing.

What is the Eli Lilly lawsuit about?

Eli Lilly filed a lawsuit alleging that Mochi changed patient tirzepatide doses in mass-batch protocol changes — applying dose adjustments to patient populations without individual provider consultation — at least five times in eight months. Mochi disputes the claims. A previous Eli Lilly lawsuit against Mochi was dismissed. The current case was active at time of publication.

What happened with the Aequita pharmacy shutdown?

In March 2025, Washington State shut down Aequita, Mochi's primary compounding pharmacy partner at the time, for sterile compounding violations. This caused significant disruption to Mochi patients — medication supply interruptions and delayed refills. Mochi transitioned to other pharmacy partners. Ask Mochi directly about its current pharmacy partners and their inspection status before enrolling.

Is the registered dietitian access really included?

Yes. 30-minute RD video visits are included in the $79/month GLP-1 membership at no additional charge. The dietitian provides nutrition counseling, meal planning, and GLP-1-specific dietary guidance. This is one of Mochi's most tangible clinical differentiators at its price point.

How does the flat-rate pricing work for compounded medications?

Mochi charges $99/month for compounded semaglutide at all doses from 0.22 mg to 2.67 mg weekly. As you titrate up, the price does not increase. The same flat rate applies at every dose level. Compounded tirzepatide is $199/month at all doses from 2.2 mg to 16.6 mg weekly. Shipping is included.

Does Mochi accept insurance for brand-name GLP-1s?

Yes — Mochi accepts insurance for brand-name medications (Wegovy, Zepbound, Ozempic, Mounjaro, and others) and has a dedicated team that handles prior authorization paperwork and appeals. The $79/month membership itself is not insurance-covered. With qualifying insurance and a manufacturer savings card, insured patients can access brand-name GLP-1s for as little as $25/month in medication cost, making total all-in cost approximately $104/month.

How do I cancel Mochi Health?

Contact Mochi's support team to cancel. The $79/month membership is non-refundable after 24 hours of enrollment. Multi-month plans cannot be prorated for early cancellation. Cancel before the next billing cycle begins to avoid additional charges — do not assume that submitting a cancellation request immediately stops billing. Request written confirmation of your cancellation.